Aardvark Therapeutics, Inc. SEC filings AARD
Aardvark Therapeutics, Inc. has 114 filings in SEC EDGAR's recent list, going back to May 24, 2019. Its latest annual report, Form ARS, was filed on Jul 10, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 23, 2026 (other events). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Other events
|
Oct 23, 2026 | Oct 23, 2026 |
| 8-K |
Current report
Other events
|
Oct 22, 2026 | Oct 22, 2026 |
| 8-K |
Current report
Officer or director change, Other events
|
Oct 8, 2026 | Oct 6, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Aug 17, 2026 | Aug 14, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| ARS | Annual report to shareholders | Jul 10, 2026 | Dec 31, 2025 |
| DEF 14A | Proxy statement | Jul 10, 2026 | Aug 14, 2026 |
| PRE 14A | Preliminary proxy statement | Jun 29, 2026 | Aug 14, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 12, 2026 | Jun 10, 2026 |
| 8-K |
Current report
Other events
|
May 14, 2026 | May 14, 2026 |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 7, 2026 | May 7, 2026 |
| EFFECT | Filing | Apr 3, 2026 | — |
| 424B5 | Prospectus supplement | Apr 3, 2026 | — |
| CORRESP | Letter to the SEC | Mar 30, 2026 | — |
| UPLOAD | Letter from the SEC | Mar 25, 2026 | — |
| 8-K |
Current report
Material agreement
|
Mar 24, 2026 | Mar 23, 2026 |
| S-8 | Employee stock plan registration | Mar 24, 2026 | — |
| S-3 | Shelf registration | Mar 23, 2026 | — |
| 10-K | Annual report | Mar 23, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 23, 2026 | Mar 23, 2026 |
| 8-K |
Current report
Other events
|
Feb 27, 2026 | Feb 27, 2026 |
| 8-K |
Current report
Officer or director change, Other events
|
Feb 12, 2026 | Feb 9, 2026 |
| 8-K |
Current report
Other events
|
Feb 10, 2026 | Feb 10, 2026 |
| 8-K |
Current report
Other events
|
Jan 12, 2026 | Jan 12, 2026 |
| 8-K |
Current report
Other events
|
Dec 10, 2025 | Dec 10, 2025 |
| 10-Q | Quarterly report | Nov 13, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 13, 2025 | Nov 13, 2025 |
| 8-K |
Current report
Other events
|
Nov 6, 2025 | Nov 5, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Nov 4, 2025 | Nov 4, 2025 |
| 8-K |
Current report
Other events
|
Oct 9, 2025 | Oct 8, 2025 |
| 8-K |
Current report
Other events
|
Sep 3, 2025 | Sep 2, 2025 |
| S-8 | Employee stock plan registration | Aug 13, 2025 | — |
| 10-Q | Quarterly report | Aug 13, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2025 | Aug 13, 2025 |
| 8-K |
Current report
Other events
|
Aug 12, 2025 | Aug 12, 2025 |
| 10-Q | Quarterly report | May 14, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations
|
May 14, 2025 | May 14, 2025 |
| 10-K | Annual report | Mar 31, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 31, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Bylaw or fiscal year change, Other events
|
Feb 14, 2025 | Feb 14, 2025 |
| S-8 | Employee stock plan registration | Feb 13, 2025 | — |
| 424B4 | Prospectus | Feb 13, 2025 | — |
| EFFECT | Filing | Feb 12, 2025 | — |
| CERT | Filing | Feb 12, 2025 | — |
| 8-A12B | Filing | Feb 10, 2025 | — |
| CORRESP | Letter to the SEC | Feb 10, 2025 | — |
| CORRESP | Letter to the SEC | Feb 10, 2025 | — |
| S-1/A | Amended registration statement | Feb 6, 2025 | — |
| CORRESP | Letter to the SEC | Jan 31, 2025 | — |
| S-1 | Registration statement | Jan 23, 2025 | — |
| DRS/A | Filing | Dec 23, 2024 | — |
| DRSLTR | Filing | Dec 20, 2024 | — |
| UPLOAD | Letter from the SEC | Dec 10, 2024 | — |
| DRSLTR | Filing | Nov 27, 2024 | — |
| DRS/A | Filing | Nov 27, 2024 | — |
| UPLOAD | Letter from the SEC | Nov 21, 2024 | — |
| DRS | Filing | Oct 24, 2024 | — |
| D | Filing | May 15, 2024 | — |
| D | Filing | Jun 7, 2021 | — |
| D | Filing | May 24, 2019 | — |
Showing 62 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AARD (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1774857
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.